Christy M. Hebner

4.2k total citations
18 papers, 999 citations indexed

About

Christy M. Hebner is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Christy M. Hebner has authored 18 papers receiving a total of 999 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 6 papers in Infectious Diseases and 4 papers in Immunology. Recurrent topics in Christy M. Hebner's work include Herpesvirus Infections and Treatments (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Respiratory viral infections research (3 papers). Christy M. Hebner is often cited by papers focused on Herpesvirus Infections and Treatments (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Respiratory viral infections research (3 papers). Christy M. Hebner collaborates with scholars based in United States, United Kingdom and France. Christy M. Hebner's co-authors include Laimonis A. Laimins, Valerie M. Weaver, Jayanta Debnath, Wade Bushman, Daniel Barnett, Marilyn Lamm, Carol A. Podlasek, J. Quentin Clemens, Juliet Lee and William Gaffield and has published in prestigious journals such as Nature Communications, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Christy M. Hebner

17 papers receiving 978 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christy M. Hebner United States 11 463 398 214 124 119 18 999
Jeffrey Kaplan United States 13 378 0.8× 204 0.5× 307 1.4× 50 0.4× 146 1.2× 28 801
Ying‐Hsiu Su United States 23 560 1.2× 456 1.1× 226 1.1× 162 1.3× 205 1.7× 51 1.3k
L Braun United States 16 456 1.0× 417 1.0× 285 1.3× 530 4.3× 110 0.9× 21 1.2k
Masayuki Yanagi Japan 14 834 1.8× 241 0.6× 107 0.5× 1.0k 8.4× 87 0.7× 24 1.4k
Anja Dankof Germany 15 155 0.3× 480 1.2× 267 1.2× 98 0.8× 348 2.9× 26 1.3k
Isao Murakami Japan 15 572 1.2× 462 1.2× 486 2.3× 23 0.2× 167 1.4× 36 1.4k
Cinzia Borgogna Italy 16 475 1.0× 249 0.6× 270 1.3× 17 0.1× 416 3.5× 38 920
Sami Remadi Switzerland 16 144 0.3× 248 0.6× 190 0.9× 15 0.1× 133 1.1× 50 787
Monia Bardelli Italy 13 406 0.9× 392 1.0× 183 0.9× 17 0.1× 527 4.4× 20 1.1k
Josephine Kang United States 20 88 0.2× 313 0.8× 354 1.7× 50 0.4× 223 1.9× 36 1.5k

Countries citing papers authored by Christy M. Hebner

Since Specialization
Citations

This map shows the geographic impact of Christy M. Hebner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christy M. Hebner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christy M. Hebner more than expected).

Fields of papers citing papers by Christy M. Hebner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christy M. Hebner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christy M. Hebner. The network helps show where Christy M. Hebner may publish in the future.

Co-authorship network of co-authors of Christy M. Hebner

This figure shows the co-authorship network connecting the top 25 collaborators of Christy M. Hebner. A scholar is included among the top collaborators of Christy M. Hebner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christy M. Hebner. Christy M. Hebner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Tan, Susanna K., Maria L. Agostini, Christy M. Hebner, et al.. (2024). A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clinical Infectious Diseases. 79(4). 1054–1061. 7 indexed citations
2.
Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2024). Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab. Future Virology. 19(5). 185–198.
3.
Schnell, Gretja, Julia di Iulio, Anil Kumar Gupta, et al.. (2023). Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study. Future Virology. 18(15). 975–990. 2 indexed citations
4.
Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2022). 1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab. Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations
5.
Pizzuto, Matteo Samuele, Fabrizia Zatta, Andrea Minola, et al.. (2020). 1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness. Open Forum Infectious Diseases. 7(Supplement_1). S635–S636. 1 indexed citations
6.
Nikitin, Pavel A., Thomas G. Gesner, Yi-Chan Lin, et al.. (2016). In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. Antimicrobial Agents and Chemotherapy. 60(8). 4961–4971. 24 indexed citations
7.
Chandramouli, Sumana, Claudio Ciferri, Pavel A. Nikitin, et al.. (2015). Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nature Communications. 6(1). 8176–8176. 98 indexed citations
8.
Rodríguez‐Torres, M., Eric Lawitz, Kris V. Kowdley, et al.. (2012). Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. Journal of Hepatology. 58(4). 663–668. 85 indexed citations
9.
Hebner, Christy M., Bin Han, Katherine M. Brendza, et al.. (2012). The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function. PLoS ONE. 7(6). e39163–e39163. 32 indexed citations
10.
Harris, Jeanette, Andrew Bae, Christy M. Hebner, et al.. (2011). 1225 CHARACTERIZATION OF VIRAL RESISTANCE MUTATIONS IN GENOTYPE 1 HCV PATIENTS RECEIVING COMBINATION THERAPY WITH A PROTEASE INHIBITOR AND A POLYMERASE INHIBITOR WITH OR WITHOUT RIBAVIRIN. Journal of Hepatology. 54. S484–S484. 6 indexed citations
11.
12.
Hebner, Christy M., Valerie M. Weaver, & Jayanta Debnath. (2008). Modeling Morphogenesis and Oncogenesis in Three-Dimensional Breast Epithelial Cultures. Annual Review of Pathology Mechanisms of Disease. 3(1). 313–339. 103 indexed citations
13.
Hebner, Christy M., et al.. (2007). Human Papillomavirus E6 Proteins Mediate Resistance to Interferon-Induced Growth Arrest through Inhibition of p53 Acetylation. Journal of Virology. 81(23). 12740–12747. 32 indexed citations
14.
Hebner, Christy M., Regina Wilson, Janet S. Rader, Miri Bidder, & Laimonis A. Laimins. (2006). Human papillomaviruses target the double-stranded RNA protein kinase pathway. Journal of General Virology. 87(11). 3183–3193. 54 indexed citations
15.
Hebner, Christy M. & Laimonis A. Laimins. (2005). Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Reviews in Medical Virology. 16(2). 83–97. 275 indexed citations
16.
17.
Lamm, Marilyn, Daniel Barnett, Christy M. Hebner, et al.. (2002). Sonic Hedgehog Activates Mesenchymal Gli1 Expression during Prostate Ductal Bud Formation. Developmental Biology. 249(2). 349–366. 133 indexed citations
18.
Lamm, Marilyn, Carol A. Podlasek, Daniel Barnett, et al.. (2001). Mesenchymal Factor Bone Morphogenetic Protein 4 Restricts Ductal Budding and Branching Morphogenesis in the Developing Prostate. Developmental Biology. 232(2). 301–314. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Kaplan Breakdown of academic impact, for papers by Ying‐Hsiu Su Breakdown of academic impact, for papers by L Braun Breakdown of academic impact, for papers by Masayuki Yanagi Breakdown of academic impact, for papers by Anja Dankof Breakdown of academic impact, for papers by Isao Murakami Breakdown of academic impact, for papers by Cinzia Borgogna Breakdown of academic impact, for papers by Sami Remadi Breakdown of academic impact, for papers by Monia Bardelli Breakdown of academic impact, for papers by Josephine Kang
Rankless by CCL
2026